iBio (NASDAQ:IBIO – Get Free Report) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday, Wall Street Zen reports.
A number of other analysts have also recently commented on IBIO. Weiss Ratings reiterated a “sell (d-)” rating on shares of iBio in a research note on Monday, September 21st. HC Wainwright started coverage on shares of iBio in a research report on Thursday, September 17th. They set a “buy” rating and a $7.00 target price on the stock. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $6.00.
Check Out Our Latest Stock Report on iBio
iBio Stock Performance
Shares of NASDAQ IBIO opened at $0.73 on Friday. The company has a market cap of $51.56 million, a PE ratio of -2.61 and a beta of 1.48. The business has a 50-day simple moving average of $0.98 and a two-hundred day simple moving average of $1.63. iBio has a fifty-two week low of $0.69 and a fifty-two week high of $3.82.
iBio (NASDAQ:IBIO – Get Free Report) last posted its quarterly earnings data on Tuesday, November 10th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.02. The company had revenue of $1.07 million for the quarter, compared to analyst estimates of $0.03 million. On average, sell-side analysts predict that iBio will post -0.35 earnings per share for the current fiscal year.
Institutional Trading of iBio
Institutional investors and hedge funds have recently bought and sold shares of the business. Landscape Capital Management L.L.C. purchased a new stake in iBio in the third quarter valued at $105,000. R Squared Ltd acquired a new stake in iBio during the 3rd quarter worth about $29,000. Squarepoint Ops LLC acquired a new stake in iBio during the 2nd quarter worth about $873,000. Headlands Technologies LLC raised its stake in shares of iBio by 333.0% during the 2nd quarter. Headlands Technologies LLC now owns 47,413 shares of the company’s stock valued at $83,000 after buying an additional 36,463 shares during the last quarter. Finally, Bank of America Corp DE raised its stake in shares of iBio by 150.8% during the 1st quarter. Bank of America Corp DE now owns 290,413 shares of the company’s stock valued at $552,000 after buying an additional 174,620 shares during the last quarter. 7.90% of the stock is currently owned by institutional investors and hedge funds.
iBio Company Profile
iBio, Inc. is a biotechnology company focused on using artificial intelligence and other computational tools to discover and develop therapies. Its research has included programs targeting obesity and metabolic diseases, as well as oncology. The company’s current approach builds on its earlier work in biologics manufacturing. Historically, iBio used its plant-based FastPharming platform to produce proteins and antibodies for research and therapeutic development. iBio is based in the United States and has shifted its focus from plant-based biologics production toward AI-enabled drug discovery.
See Also
- Five stocks we like better than iBio
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for iBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iBio and related companies with MarketBeat.com's FREE daily email newsletter.
